Literature DB >> 19955778

Blood-brain barrier as a regulatory interface.

William A Banks.   

Abstract

The blood-brain barrier (BBB) is an important component of the communication network that connects the central nervous system and peripheral tissues in the control of feeding-related behaviors. Specifically, the BBB acts as an interface that restricts and regulates the exchange of substances between the CNS and blood. Many of the eating-related peptides and regulatory proteins produced by peripheral tissues and with receptors in the brain have been found to cross the BBB. The consequences of BBB permeability to these substances can be viewed from various perspectives. Here, we briefly consider five views relating the BBB and eating. A view of physiologic integration emphasizes the BBB as a conduit that controls a humoral-dependent signaling between the CNS and peripheral tissues. A view of regulation emphasizes that the transporters for many of the eating-related hormones are themselves regulated by physiologic events. This means that blood-to-brain signaling across the BBB is state-dependent and adaptable to the needs of the organism. A view of pathologic dysfunction shows how dysregulation of BBB transporters can result in disease. Resistance to leptin caused by its decreased transport across the BBB in obesity is an example. An evolutionary view emphasizes how the role of the BBB in eating may have evolved and how adaptations to one set of eating conditions can result in maladaptations under other conditions. Finally, the implications of these views for drug development targeted at obesity or anorexia is explored. Overall, these views show the BBB is an integral part of the physiology of eating. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19955778     DOI: 10.1159/000264398

Source DB:  PubMed          Journal:  Forum Nutr        ISSN: 0067-8198


  24 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

Review 2.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

3.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

Review 4.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

5.  Impacts of blood-brain barrier in drug delivery and targeting of brain tumors.

Authors:  Yadollah Omidi; Jaleh Barar
Journal:  Bioimpacts       Date:  2012-02-02

Review 6.  In vitro blood-brain barrier models: current and perspective technologies.

Authors:  Pooja Naik; Luca Cucullo
Journal:  J Pharm Sci       Date:  2011-12-27       Impact factor: 3.534

7.  Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.

Authors:  Janet Hsu; Jeff Rappaport; Silvia Muro
Journal:  Pharm Res       Date:  2014-02-21       Impact factor: 4.200

Review 8.  Cell-culture models of the blood-brain barrier.

Authors:  Yarong He; Yao Yao; Stella E Tsirka; Yu Cao
Journal:  Stroke       Date:  2014-06-17       Impact factor: 7.914

Review 9.  In vitro cerebrovascular modeling in the 21st century: current and prospective technologies.

Authors:  Christopher A Palmiotti; Shikha Prasad; Pooja Naik; Kaisar M D Abul; Ravi K Sajja; Anilkumar H Achyuta; Luca Cucullo
Journal:  Pharm Res       Date:  2014-08-07       Impact factor: 4.200

10.  Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.

Authors:  Jason Papademetriou; Carmen Garnacho; Daniel Serrano; Tridib Bhowmick; Edward H Schuchman; Silvia Muro
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.